BUILDING STRENGTH
changing lives

CONTACT:
Heidi Wallis, Vice President
heidi@creatineinfo.org

FOR IMMEDIATE RELEASE

Dr. Yiumo Chan Joins Association for Creatine Deficiencies' Scientific Board

Carlsbad, CA (October 26, 2017)- The Association for Creatine Deficiencies (ACD) welcomes Dr. Yiumo Chan as its newest Scientific Medical Advisory Board member (SMAB). The organization represents the 3 creatine deficiencies, CTD, AGAT and GAMT and is currently expanding its medical board to consist of world's leading experts in creatine.

Whitnie Strauss, ACD President, remarked, "Dr. Chan has been conducting translational research and developing treatments for genetic diseases in both academic and industry settings and we are very excited to bring this type of experience to the ACD's SMAB."

About Dr. Yiumo Chan, Ph.D: Dr. Chan's focus is on various forms of muscle, neurological and metabolic diseases. Dr. Chan received his B.Sc and Ph.D. degrees from the University of Chicago (the genetic basis of Weber-Cockayne Epidermolysis Bullosa Simplex (WC-EBS): Genetic and functional analyses of keratin mutations) and completed his post-doctoral training with Dr. Louis Kunkel at Children's Hospital Boston focusing on limb-girdle muscular dystrophies (LGMD). Dr. Chan was a Staff Scientist in Geisinger Medical Center and Senior Scientist in Carolinas Medical Center where he developed animal models for dystroglycanopathies which affect both muscle and brain. Subsequently, he joined Ultragenyx Pharmaceutical Inc. and was Research Lead for GNE Myopathy (pre-IND to phase III) and other small molecule programs. Dr. Chan also developed an interest in energy metabolism with knowledge and experience in creatine metabolism. He has authored over 35 peer-reviewed articles and has in-depth knowledge of both disease mechanisms and drug development process. Dr. Chan also serves as Scientific Advisory Board Member for other non-profit patient organizations, including CURE CMD.

About ACD: The Association for Creatine Deficiencies' mission is to eliminate the challenges of CCDS. ACD is committed to providing patient, family, and public education to advocate for early intervention through newborn screening, and to promote and fund medical research for treatments and cures for Cerebral Creatine Deficiency Syndromes. Because CCDS mimic symptoms of other medical conditions, patients are often first diagnosed with autism, cerebral palsy, epilepsy, and other disorders. Proper diagnosis and early intervention are critical to establishing screening and treatments needed to improve life quality and longevity for the CCDS patient. For more information regarding ACD, please visit http://www.creatineinfo.org.